Tirzepatide, targeting both GIP and GLP-1 receptors, demonstrates high rates of severe gastrointestinal events and treatment discontinuation alongside its established glucose and weight benefits. The analysis reveals concerning patterns of skeletal muscle loss during treatment, potentially counteracting metabolic improvements through sarcopenia development. Rare but serious risks include gallbladder complications and thyroid disorders requiring ongoing surveillance. This comprehensive safety evaluation arrives at a critical juncture as tirzepatide gains rapid global adoption for diabetes and obesity management. The dual-receptor mechanism that drives its superior efficacy compared to single GLP-1 agonists may inherently increase adverse event severity. The muscle mass concerns are particularly significant given that preserving lean tissue is fundamental to healthy aging and metabolic function. The authors' call for precision phenotyping represents a necessary evolution in prescribing practices, moving beyond population-level efficacy data toward individualized risk assessment. This safety profile analysis suggests that while tirzepatide marks a therapeutic breakthrough, its widespread deployment requires more nuanced patient selection and monitoring protocols to balance transformative benefits against emerging safety signals.